This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete report on H2, 2015 Pipeline Review of “Plaque Psoriasis” addition with 69 market data tables and 15 figures, spread across 249 pages is http://www.rnrmarketresearch.com/plaque-psoriasis-psoriasis-vulgaris-pipeline-review-h2-2015-market-report.html .
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by professional's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Companies Discussed/Mentioned in this Research:
3SBio Inc., Amgen Inc., AstraZeneca Plc, Avesthagen Limited, Avexxin AS, BIOCAD, Biocon Limited, Bionovis SA, Can-Fite BioPharma Ltd., Celgene Corporation, Celltrion, Inc., Creabilis SA, Delenex Therapeutics AG, Dermira Inc., Epirus Biopharmaceuticals, Inc., Forward Pharma A/S, Galectin Therapeutics, Inc., Genor BioPharma Co., Ltd., GlaxoSmithKline Plc, Hetero Drugs Limited, Idera Pharmaceuticals, Inc., Invion Limited, Johnson & Johnson, Kadmon Corporation, LLC, Kineta, Inc., Kyowa Hakko Kirin Co., Ltd., LEO Pharma A/S, Lipidor AB, Mabion SA, Mabtech Limited, Maruho Co., Ltd., Momenta Pharmaceuticals, Inc., Mycenax Biotech Inc., Oncobiologics, Inc., Pfizer Inc., Promius Pharma, LLC, Protalix BioTherapeutics, Inc., Provectus Biopharmaceuticals, Inc., R-Tech Ueno, Ltd., TetraLogic Pharmaceuticals, Therapeutic Proteins International, LLC, UCB S.A. and Valeant Pharmaceuticals International, Inc.
Drugs Profile Discussed in this Research:
(betamethasone dipropionate + calcipotriene), (calcipotriene + betamethasone dipropionate), (calcipotriene + betamethasone), adalimumab biosimilar, AM-001, AVX-001, betamethasone valerate + maxacalcitol, bimekizumab, bleselumab, brodalumab, calcipotriene, CC-90005, CT-327, dalazatide, DFD-01, DFD-06, dimethyl fumarate, DLX-105, DNX-114, DNX-514, DRM-02, etanercept biosimilar, GK-664S, GRMD-02, GSK-2981278, guselkumab, IDP-118, IDP-122, IMO-8400, IMP-731, infliximab biobetter, infliximab biosimilar, INV-103, KD-025, LEO-32731, LP-0113, M-7040, MOL-4239, MOL-4249, pefcalcitol, PF-04965842, PF-06700841, PH-10, piclidenoson, RTU-1096, SHP-141, tofacitinib, toreforant tartrate, UCB-5857 and ustekinumab biosimilar
Inquire before buying for this report http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=441635 . (This is a premium report price at US$2000 for a single user PDF license)
- The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Plaque Psoriasis (Psoriasis Vulgaris) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy:
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore More Research Report on Dermatology Therapeutics Market.
In the era of global warming, skin problems have taken a toll such that every day is celebrated to be the birthday of a new kind of dermatologic disease. People are getting addicted to more of the skin care products. In that sense, the market of Dermatology therapeutics seems to be in the best of times such that the investors are getting double return from the pharmaceutical industry. After all, most of the humans aim to beautify the envelope of their internal world.
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries